Clinical, cosmetic and investigational dermatology · 2025
Cutis verticis gyrata in a Patient with Familial presenile sebaceous hyperplasia Presenting as "Leonine facies": A Rare Case.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sutedja Eva Krishna, Sutedja Endang, Ruchiatan Kartika, Faldian Yogi, Yogya Yuri, Dwiyana Reiva Farah, Maharani Retno Hesty, Budiarsa Marshel
Аннотация
Cutis verticis gyrata (CVG) is a rare dermatological disorder characterized by thickened, gyriform folds and ridges of the skin, predominantly affecting the head and face. Based on etiology, it is classified into primary and secondary forms. Familial presenile sebaceous hyperplasia (FPSH), a rare variant of sebaceous hyperplasia, follows an autosomal dominant inheritance pattern with incomplete penetrance and variable severity among family members. We report a case of a 60-year-old male who presented to the Dermatology and Venereology Department, Hasan Sadikin General Hospital, Bandung, with thick plaques and deep furrows on the forehead, giving a "leonine facies" appearance. These lesions first appeared 25 years ago and progressively increased in number and spread to the neck and chest. Similar symptoms were observed in his twin brother and son. Investigations including skin slit smears, blood tests, serum biochemistry, imaging, and testosterone levels were unremarkable. Histopathological examination of facial papules and nodules showed enlarged sebaceous glands in the dermis, supporting the diagnosis of sebaceous hyperplasia. The patient was diagnosed with FPSH associated with CVG. Although rare, both conditions may be linked to systemic abnormalities, highlighting the importance of comprehensive evaluation. There is no definitive treatment for FPSH or CVG; current management is mainly cosmetic. Isotretinoin, with its sebocyte-suppressing effect, may reduce gland size but has a high recurrence rate upon discontinuation. Early recognition and a multidisciplinary approach are crucial to prevent further progression, particularly in older patients.